USPTO serial 79392961
INDIVUMED THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 31, 2026
- Examiner
- SEVERSON, JUSTIN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INDIVUMED THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
R. Glenn Schroeder
R. Glenn Schroeder Schroeder Law PC110 Cooper Street #605Babylon, NY 11702United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, therapeutic and veterinary preparations, in particular medicines for human beings and animals for the treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; human and animal sample materials, for medical purposes, namely, Allograft or Xenograft tissue preparations, tissue cuts, blood plasma, blood serum, ascites, cerebrospinal fluid, human and animal urine and human and animal stool; test kits of human and animal samples materials for medical purposes comprising medical diagnostic reagents for medical diagnostic purposes; therapeutic preparations for the treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system, made using molecular biological, molecular genetic, genetic engineering, immunological and biotechnical methods; medical diagnostic reagents; clinical diagnostic reagents for medical use; medical diagnostic test strips for blood analysis and urine analysis; diagnostic preparations and materials for medical or veterinary purposes; diagnostic reagents for medical use; diagnostic substances for medical use; biological material collections, namely, biological tissue samples, blood plasma samples and blood serum samples for medical purposes; cancer material collections, namely, biological tissue samples, blood plasma samples and blood serum samples for cancer diagnosis and treatment purposes; medical sample collections; biological sample collections, namely, biological tissue samples, blood plasma samples and blood serum samples for medical purposes; biopsy material collections, namely, biological tissue samples; all the afore-mentioned in particular with regard to the field of oncology | ACTIVE | — |
| 009 | Apparatus and instruments for scientific research in laboratories, in particular apparatus for analysis of biologic samples and for the qualitative and quantitative recognition of analytes in samples, and the identification of sample types, namely, electronic analysers and analysers for the qualitative and quantitative recognition of samples and identification of the sample type and molecular states; apparatus for the typing of tissues and tissue samples, namely for the molecular analysis of biological samples such as tissue, cuts, blood, serum, plasma, ascites, cerebrospinal fluid, urine or stool; apparatus for recording, transmission or reproduction of data, namely, hard disk drives, blank hard computer discs, solid-state drives, and USB hardware; blank magnetic data carriers, data processing equipment and computers | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research and design for others in the field of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; research services in the field of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; design and development of computer hardware and software, in particular computer programs; scientific research for medical purposes, in particular molecular biological, immunological and histological laboratory services, in particular research and development in the field of human medical and veterinary medical diagnostics and therapy; typing of tissue and tissue samples, in particular using molecular biological, immunological, genetic engineering and histological methods for research purposes; collection of human and animal biospecimen and clinical data for the diagnosis and treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; generation of, by means of scientific computer-aided sample analysis, and provision of, by means of cloud storage and online access of multi-omics data from human and animal biospecimen, in particular genomic, epigenomic, proteomic, phosphorproteomic, RNA, transcriptomic, lipidomic and metabolomic data for the diagnosis and treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; medical research laboratory services, namely, typing of tissue and tissue samples, in particular using molecular biological, immunological, genetic engineering and histological methods; database design and development; providing online non-downloadable computer software platforms for hosting databases; installation, maintenance and updating of database software; providing scientific research information and results in the field of diagnosis and treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system from an online searchable database; programming of databases; collecting genetic, medical, biomedical, biologic, chemical and biochemical data and information, in particular information generated through the use of imaging techniques, the use of liquid biopsy methods, the use of histopathological analysis and procedures, the use of genetic analysis and the use of genomics, proteomics, transcriptomics, metabolomics, lipidomics and/or glycomics studies and analysis for medical research; scientific and laboratory analysis using bioinformatics and computational biology in the field of diagnosis and treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; consultancy relating to research and development in the field of therapeutics and pharmaceutics; pharmaceutical and therapeutical products development; pharmaceutical research and development services; research and development for the pharmaceutical and biotechnological industry; services for research and development in the pharmaceutical and biotechnical field; services for research and development regarding pharmaceutics, therapeutics, diagnostics, especially for the medical examination and medical care of patients | ACTIVE | — |
| 044 | Medical analysis in connection with the treatment of individuals, namely, medical analysis of X-rays and blood samples, namely, medical testing for diagnostic and treatment purposes; provision of analysis files which provide medical information to medical and scientific personnel and allows members to update their medical treatment or scientific research plans; medical clinic services; pharmaceutical advisory services; medical analysis services using bioinformatics and computational biology, for patient diagnostic and treatment purposes; providing supporting services and advice to hospitals and other medical care centers, namely, collecting and stabilizing of human and animal biospecimens, and the collection of related clinical data for patient diagnostic and treatment purposes; all the afore-mentioned in particular with regard to the field of oncology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Indivumed GmbH
- Other trademarks owned by Indivumed GmbH
- Other trademarks owned by Indivumed GmbH
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named INDIVUMED THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 22, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 1, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 11, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 9, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 30, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 31, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 31, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 10, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 10, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 4, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 20, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 20, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 20, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 20, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 20, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 19, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 3, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 3, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 3, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 3, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 3, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 25, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 25, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 25, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 6, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 31, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 31, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 31, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 19, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 27, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 27, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 25, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 24, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 12, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 8, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 4, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |